Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride doesn't affect oral testosterone undecanoate, and high DHT levels may cause acne, prostate issues, and hair loss.

5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.

The developed model can predict effective 5-alpha-reductase enzyme inhibitors.

The document's conclusion cannot be provided because the document is not available or cannot be read.

Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.

Some dibenzo compounds might help treat cancer with fewer side effects.

Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.

Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.

Oral contraceptives and antiandrogens are the best treatments for hirsutism.

Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.

Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.

Tamsulosin with Serenoa repens is as effective as with 5-alpha-reductase inhibitors but causes fewer side effects.

Combining a GnRH agonist with a low-dose oral contraceptive is more effective and safer for treating hirsutism than using either alone.

Different anti-androgen medications can help treat excessive hair growth, but the right choice depends on accurate diagnosis.

Benzo[c]quinolizin-3-ones are effective nonsteroidal inhibitors of human steroid 5α-reductase 1.

Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.

Finasteride effectively inhibits the enzyme steroid 5 alpha-reductase II.

Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.

Antiandrogens are somewhat effective in reducing excessive hair growth in women.

Certain derivatives are more effective 5α-reductase type 2 inhibitors than finasteride.

A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.

Combination therapy is more effective for prostate volumes over 60 ml.

Changing the C-ring structure in certain compounds can make them better at blocking a specific human enzyme.

Regulatory challenges make developing combination therapies in urology difficult and costly.

A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.

These medications for BPH have known risks and may have new side effects.